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Directed Evolution of Adeno-associated Virus
for Enhanced Gene Delivery and Gene Targeting
in Human Pluripotent Stem Cells
Prashanth Asuri1–3, Melissa A Bartel1–3, Tandis Vazin1–3, Jae-Hyung Jang1–4, Tiffany B Wong5 and
David V Schaffer1–3
Department of Chemical and Biomolecular Engineering, University of California, Berkeley, California, USA; 2Department of Bioengineering,
University of California, Berkeley, California, USA; 3The Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA;
4
Department of Chemical and Biomolecular Engineering, Yonsei University, Seoul, Korea; 5Department of Molecular and Cell Biology,
University of California, Berkeley, California, USA
1

Efficient approaches for the precise genetic engineering
of human pluripotent stem cells (hPSCs) can enhance
both basic and applied stem cell research. Adenoassociated virus (AAV) vectors are of particular interest for
their capacity to mediate efficient gene delivery to and
gene targeting in various cells. However, natural AAV serotypes offer only modest transduction of human embryonic and induced pluripotent stem cells (hESCs and
hiPSCs), which limits their utility for efficiently manipu
lating the hPSC genome. Directed evolution is a powerful
means to generate viral vectors with novel capabilities,
and we have applied this approach to create a novel AAV
variant with high gene delivery efficiencies (~50%) to
hPSCs, which are importantly accompanied by a considerable increase in gene-targeting frequencies, up to
0.12%. While this level is likely sufficient for numerous
applications, we also show that the gene-targeting efficiency mediated by an evolved AAV variant can be further
enhanced (>1%) in the presence of targeted doublestranded breaks (DSBs) generated by the co-delivery of
artificial zinc finger nucleases (ZFNs). Thus, this study
demonstrates that under appropriate selective pressures,
AAV vectors can be created to mediate efficient gene
targeting in hPSCs, alone or in the presence of ZFNmediated double-stranded DNA breaks.
Received 26 May 2011; accepted 27 October 2011; published online
22 November 2011. doi:10.1038/mt.2011.255

Introduction
The capacity to mediate high efficiency gene delivery to human
pluripotent stem cells (hPSCs) has numerous applications, ranging from the study of specific genes in stem cell self-renewal and
differentiation to the directed differentiation of stem cells into
specific lineages for therapeutic application. Furthermore, precise manipulation of the human stem cell genome using genetargeting techniques that exploit the natural ability of cells to

perform homologous recombination (HR) has broad applications
and implications, including safe harbor integration of genes for
basic or therapeutic application, creating in vitro models for investigating human development and disease, and high-throughput drug
discovery and toxicity studies.1,2 However, while gene delivery and
gene targeting are well established for various mammalian somatic
cells,3 a readily generalized approach for efficient gene expression
and gene targeting in hPSCs requires further development.
Current methods to deliver genes to hPSCs range from viral
vectors to plasmid-based transient gene expression. Lentiviral
vectors—which are highly efficient and result in long-term gene
expression—have been extensively employed in numerous studies
in human stem cells.4 However, transient expression is desirable in
some cases, such as for the temporary overexpression of regulatory
signals to manipulate stem cell fate decisions.5,6 Also, vector integration into the genome can risk insertional mutagenesis, a potential
concern for downstream clinical application.4 As an alternative,
electroporation can be used to achieve transient gene expression,
though this method can suffer from low transfection efficiencies and
moderate toxicity in human stem cells.7 In addition to gene delivery, there is a need to develop efficient gene-targeting methods that
rely on HR to introduce permanent and sequence-specific genome
modifications in hPSCs. Several impressive studies have demonstrated successful gene targeting in hPSCs, though the initial rates
reported using conventional methodologies are low (10−7–10−5 correctly targeted cells for every original cell in the population), which
necessitates the use of positive and negative selection to improve the
overall efficiency and specificity of the process.8,9
Recently, several approaches have been utlized to improve
gene targeting in hPSCs, including the introduction of doublestranded breaks (DSBs) into the cellular genome by engineered
nucleases.10–14 Such breaks stimulate the cellular DNA repair
machinery and thereby greatly enhance the rate of homologous
recombination with a donor DNA.15 For example, Zou et al. found
that cotransfection of plasmids containing the donor DNA and
zinc finger nucleases (ZFNs) significantly increased gene targeting in hPSCs up to a frequency of 0.24% (~1 targeted cell in

The first two authors contributed equally to this work.
Correspondence: David V Schaffer, Department of Chemical and Biomolecular Engineering, University of California, Berkeley, 274 Stanley Hall, Berkeley,
California 94720-1462, USA. E-mail: schaffer@berkeley.edu
Molecular Therapy vol. 20 no. 2, 329–338 feb. 2012

329

© The American Society of Gene & Cell Therapy

AAV for Enhanced Gene Delivery and Targeting

Results
Evaluation of wild-type serotypes
There are numerous naturally occurring AAV variants and
serotypes, each of which has different protein capsids and thus
330
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415 original cells), as compared to less than 1 targeted cell per 106
original cells in the absence of the ZFNs.13 More recently, a new
approach has been described to engineer DNA-binding specificities based on transcription activator–like effector (TALE) proteins
from Xanthomonas plant pathogens and artificial restriction
enzymes generated by fusing TALEs to the catalytic domain of
FokI was used to generate discrete edits or small deletions within
endogenous human genes at efficiencies of up to 25%.16 However,
while the utilization of ZFNs and transcription activator–like
effector nucleases (TALENs) to enhance gene-targeting efficiencies in hPSCs is highly promising, the approach entails custom
engineering of a new nuclease for each new target locus, which
requires labor, time, and resources.
Adeno-associated virus (AAV) is a nonpathogenic, nonenveloped virus containing a 4.7 kb single-stranded DNA genome that
encodes the structural proteins of the viral capsid (encoded by the
cap gene) and the nonstructural proteins necessary for viral replication and assembly (encoded by the rep gene), flanked by short
inverted terminal repeats.17 Recombinant versions of AAV can
be created by inserting a sequence of interest in place of rep and
cap, and the resulting recombinant vectors can efficiently deliver a
transgene and safely mediate long-term gene expression in dividing and nondividing cells of numerous tissues.17 Such AAV-based
vectors have proven safe, efficient, and recently very effective for
clinical application.18,19
An interesting property of AAV is that, as demonstrated
by Russell and colleagues, AAV vector genomes carrying genetargeting constructs can mediate HR with target loci in a cellular genome at efficiencies 103–104-fold higher than plasmid
constructs.3 The AAV genome’s inverted terminal repeats, which
apparently mediate its entry into the RAD51/RAD54 component
of the cellular HR pathway, play a central role in this property.20
AAV-mediated gene targeting has been successfully applied to cells
that AAV can effectively transduce, but naturally occurring AAV
variants are typically inefficient at infecting a number of stem cell
types, particularly human embryonioc stem cells (hESCs).21,22
We have implemented directed evolution—a rapid, highthroughput selection approach to create and isolate novel mutants
from millions of genetic variants—to rapidly engineer AAV variants with desired gene delivery properties in the absence of the
extensive mechanistic information typically required for rational
biomolecular design. Recent work highlights the ability to apply
directed evolution to create AAV mutants with altered receptor
binding, neutralizing antibody-evasion properties, and altered cell
tropism in vitro and in vivo.23–29 Likewise, we have recently demonstrated that directed evolution can yield novel AAV variants that
enhance gene delivery and gene targeting in neural stem cells.21
Here, we implement this approach to create new AAV mutants
with the enhanced capacity to infect and, subsequently, increase
the efficiency of AAV-mediated gene targeting in hPSCs, both
in the presence and absence of ZFN-mediated double-stranded
DNA breaks.
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Figure 1 Gene expression in hESCs mediated by various AAV serotypes. HSF-6 cells were infected with numerous natural AAV serotypes at
a MOI of 10,000. Transduction efficiency was assessed as the percentage
of GFP positive cells measured by flow cytometry 48 hours postinfection.
Error bars indicate standard deviation (n = 3). AAV, adeno-associated
virus; GFP, green fluorescent protein; hESC, human embryonic stem cell;
MOI, multiplicity of infection.

somewhat different gene delivery properties for various cell types
and tissues.30 AAV serotypes 1–6 and 8 were tested to assess their
potential for hESC gene delivery. Initially, HSF-6 hESCs were
infected with AAV vectors carrying green fluorescent protein
(GFP) complementary DNA at a multiplicity of infection (MOI)
of 10,000, and 48 hours postinfection, flow cytometry was used to
determine the percentage of cells that express GFP and were thus
infected by AAV. The most efficient was AAV6 (Figure 1); however, its low delivery efficiency (14.75 ± 3.08% GFP positive cells)
places significant limitations on the fraction of cells that express a
transgene or could undergo gene targeting. These results are consistent with earlier reports showing that natural AAV serotypes
are typically inefficient in gene delivery to human stem cells,31,32
thus demonstrating the need to find, or evolve, an AAV variant
capable of more efficient transduction.

AAV library generation and selection through
directed evolution
The AAV capsid proteins, encoded by the cap gene, determine the
virus’ ability to infect cells through their initial binding to various cell-surface receptors, intracellular trafficking, and entry into
the nucleus. Directed evolution is a high-throughout approach
that involves the creation and functional selection of libraries of
genetic mutants to isolate novel variants with desirable properties. We implemented a directed evolution strategy to create AAV
variants capable of mediating efficient gene delivery to hESCs
(Figure 2a). Briefly, hESCs were infected with pools of virus
variants created using several different techniques: a library in
which AAV2 and AAV6 cap were subjected to error-prone PCR,
a “shuffled” library composed of random cap chimeras of seven
parent AAV serotypes,24 an AAV2 cap library with random 7-mer
inserts,33 and AAV2 cap with substituted loop regions.25 Following
infection with AAV libraries (Figure 2a, step 4) and amplification of the infectious AAV variants through adenovirus superinfection—as AAV requires a helper virus such as adenovirus to
induce replication—(step 5), the resulting titre of AAV rescued
from each library condition was quantified and compared to titres
of recovered wild-type AAV2 as a metric for relative success of
www.moleculartherapy.org vol. 20 no. 2 feb. 2012
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Figure 2 Directed evolution of AAV and hPSC transduction by AAV 1.9. (a) Schematic representation of directed evolution. 1) A viral library
is created by mutating the cap gene. 2) Viruses are packaged in HEK293T cells using plasmid transfection, such that each particle is composed of
mutant capsid surrounding the cap gene encoding that protein capsid. 3) Viruses are harvested from 293 cells and purified. 4) The viral library is
introduced to the HSF-6 hESCs in vitro. 5) Successful viruses are amplified and recovered using adenovirus rescue. 6) Successful clones are enriched
through repeated selections. 7) Isolated viral DNA reveals selected cap genes. 8) Selected cap genes are mutated again to serve as a new starting
point for selection. (b) Molecular model of the full AAV2 capsid, based on the solved structure,51 shows the location of the R459G mutation (blue) on
the surface of the capsid (VP3 region), near the threefold axis of symmetry and residues known to be important for heparin and FGF receptor binding (pink). (c) AAV-mediated gene expression in hESCs. HSF-6 cells were infected with selected mutants at a MOI of 10,000. Transgene expression
was assessed as the percentage of GFP positive cells measured by flow cytometry 48 hours postinfection. Error bars indicate the standard deviation
(n = 3), *P < 0.01. (d) Elevating the MOI increases transduction. HSF-6 cells were infected with AAV1.9 at MOIs of 1,000, 10,000, and 100,000.
Transgene expression was assessed as the percentage of GFP positive cells measured by flow cytometery 48 hours postinfection. Error bars indicate
standard deviation (n = 3), *P < 0.01. (e) AAV1.9-mediated gene expression in hPSCs. HSF-6 hESCs, human dermal fibroblast-derived hiPSCs, human
MSC-derived hiPSCs, and H1 hESCs were infected at a MOI of 10,000. Transgene expression was assessed as the percentage of GFP positive cells
measured by flow cytometry 48 hours postinfection. Error bars indicate the standard deviation (n = 3), *P < 0.01. (f) In vitro analysis of AAV1.9
tropism. Variant AAV1.9 (white), selected on hESCs, is less infectious on AAV-permissive cell types (HEK293T, CHO) than recombinant AAV2 (black)
and AAV6 (gray), but more infectious on HSF-6 hESCs. Error bars indicate standard deviation (n = 3), *P < 0.01. (g) HSF-6 cells infected by AAV1.9
maintain pluripotency marker expression. HSF-6 cells infected with AAV1.9 encoding GFP at an MOI of 100,000 were fixed and immunostained
1 week after infection for the presence of GFP (green) and the pluripotency marker Nanog (red). AAV, adeno-associated virus; FGF, fibroblast growth
factor; GFP, green fluorescent protein; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; MOI, multiplicity of infection;
MSC, mesenchymal stem cell.

the selection. For each selection step, viral pools from the library
produced higher viral titres than wild-type AAV2 at MOIs of both
10 and 100 (data not shown). These viral pools were then used as
the starting point for the subsequent selection step (step 6). After
three such selection steps, the successful viral cap genes were isolated (step 7) and tested individually to identify variants with the
most efficient gene delivery. In addition, the cap genes isolated
after the third selection step were subjected to an additional round
Molecular Therapy vol. 20 no. 2 feb. 2012

of evolution, i.e., additional mutagenesis (step 8) and three selection steps, to further increase the fitness of the pool.

Increased transduction efficiency of the novel
evolved AAV variant in hESCs
Nine cap variants from each library isolated after the third selection
step of the first round of evolution were fully sequenced, and the
AAV capsid protein variations and the frequency with which each
331
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Table 1 Summary of variants isolated from three rounds of selection
against hESCs
Mutations

EP 1.1

S85G, R459G

Frequency

3/9

EP 1.3

R459G, V600A

1/9

EP 1.5

S85G, R447S, R459G

1/9

EP 1.8

R447S, R459G

2/9

EP 1.9

R459G

2/9

Protein sequence features and the frequency of appearance during analysis are
listed for each clone isolated from the EP AAV2/AAV6 library.
AAV, adeno-associated virus; hESC, human embryonic stem cell.

b
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Clone name

delivered to each cell (Supplementary Materials and Methods
and Supplementary Figure S1). Interestingly, sequencing of cap
variants isolated after an additional round of mutagenesis to the
cap library and three additional selection steps all matched the
sequence of AAV1.9 (data not shown).
AAV1.9 was isolated through multiple rounds of selection
using the HSF-6 hESC line; however, the increase in gene delivery efficiency also extended to the broadly utilized H1 hESC line,
as well as induced pluripotent cell lines including mesenchymal
stem cell (MSC)-derived, and dermal fibroblast-derived hiPSC
lines (Figure 2e).34 In addition, while AAV1.9 is capable of higher
gene delivery efficiency to hESCs and hiPSCs, it is less infectious
towards several cell types typically permissive to AAV infection (Figure 2f), indicating that in this case directed evolution
yielded a variant that efficiently and somewhat selectively transduces an ordinarily nonpermissive cell. Furthermore, the hESCs
maintained pluripotency marker expression following infection,
assessed via Nanog immunostaining (Figure 2g).
The R459G mutation in AAV1.9 lies close to but not within
the heparin or fibroblast growth factor (FGF) receptor binding
domains on the AAV capsid surface (Figure 2b), though it could
conceivably modulate binding to the cell surface. To determine
whether the amino acid 459 mutation alters the heparin-binding
properties of the variant, AAV2, AAV6, and AAV1.9 were analyzed using heparin column chromatography, which can provide a
measure of the heparin-binding affinity of AAV variants. Despite
its mutation residing outside the reported heparin-binding
domain,35 and despite the loss of a positively charged residue,
AAV1.9 displays a higher affinity for heparin compared to the
parental serotype AAV2, as indicated by the higher NaCl concentration needed to elute the majority of AAV1.9 from the heparin
column. (Figure 3a). However, in vitro transduction of CHO and
pgsA (a mutant CHO cell line lacking surface glycosaminoglycans
(GAGs)) cells showed that AAV1.9 had less dependence on cellsurface heparan sulfate proteoglycans (AAV2’s primary receptor)36
for cell transduction (Figure 3b). Furthermore, while it exhibited
higher transduction levels, AAV1.9 bound to hESCs at levels similar to AAV2 (Figure 3c). Collectively, these data indicate that the

4.0
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2.5
2.0
1.5
1.0
0.5
0.0

Amount transduced
Amount bound
90
80
70
60
50
40
30
20
10
0
AAV2 AAV6 AAV1.9

*

% Virus bound

clone was detected in the error-prone PCR-mutagenized AAV2
and AAV6 library are shown in Table 1. The cap genes of these
variants were also used to package recombinant AAV carrying
the GFP gene, under the control of the cytomegalovirus (CMV)
promoter. These recombinant AAV variants were then used to
infect hESCs, and the gene delivery efficiency of each virus was
measured via flow cytometry. Of the mutants isolated from the
error-prone PCR-mutagenized AAV2 and AAV6 library, the variant AAV EP 1.9 (or AAV1.9), which carries a single-point mutation (R459G) (Figure 2b), showed the highest infection efficiency
at 28.25 ± 1.68% GFP positive cells, representing an approximately
threefold increase over AAV2 (its parental serotype) and a twofold increase over AAV6 (the best serotype) at an MOI of 10,000
(Figure 2c). Variants isolated from the shuffled, 7-mer insertion,
and substituted loop region libraries were sequenced and analyzed
as well. Variants from these libraries showed increased infection
efficiency compared to AAV2, but not AAV6 (data not shown). At
an MOI of 100,000, the variant AAV1.9 achieved a strong infection efficiency of 48.21 ± 12.92% GFP positive cells (Figure 2d).
It should be noted that hESCs grow as colonies that are typically
multilayered, making accessing and infecting all of the cells in a
colony difficult. However, AAV1.9 provides an increase in gene
delivery efficiency, by an increase in the number of cells infected
(Figure 2c), an increase in the relative fluorescence intensity
of infected cells (approximately threefold higher than AAV6),
and a significantly increased number of donor DNA molecules

Elution solution (mmol/l NaCI)

Figure 3 Mechanistic analysis of transduction by variant AAV. (a) AAV1.9 has a higher affinity for heparin than AAV2 and AAV6. The heparin affinity column chromatogram of recombinant AAV2 (black), AAV6 (gray), and AAV1.9 (white) is shown, where virus was eluted from the column using
increasing concentrations of NaCl. Virus was quantified using qPCR. (b) In vitro characterization of AAV1.9 HSPG dependence. CHO (black) and pgsA
(white) cells were transduced to demonstrate the decrease in HSPG dependence of AAV1.9 compared to AAV2. Error bars indicate standard deviation
(n = 3), *P < 0.01. AAV, adeno-associated virus; hESC, human embryonic stem cell, qPCR, quantitative PCR. (c) In vitro characterization of AAV1.9
binding affinity. AAV1.9 and its parental serotype AAV2 bind hESCs to similar extents, yet AAV1.9 is capable of significantly higher transduction of
hESCs. Error bars indicate standard deviation (n = 3), *P < 0.01.
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R459G mutation may exert its effects after initial docking to the
cell surface, though future studies will be needed to elucidate its
mechanism of enhanced hESC infection.

Enhanced gene-targeting efficiency of the novel
evolved AAV variant in hESCs
We assessed the ability of the novel variant to mediate gene targeting in hPSCs. To do so, we employed a mutated GFP-based
reporter system, previously described by Zou et al.13 Briefly, GFP
complementary DNA containing a 35 bp insertion harboring a
stop codon (GFP∆35) was introduced into HSF-6 hESCs using a
lentiviral vector (see Materials and Methods and Figure 4a). The
donor construct (t37GFP) consisted of a promoter-less, nonfunctional GFP with a 37 bp 5′ truncation, as well as 290 nucleotides
35 bp insert
UB

GFP∆35

IRES

PuroR

Lentiviral vector, GFP∆35

LTR

ZFNs site
ITR

t37GFP

IRES

PuroR

Donor AAV vector, t37GFP

ITR

37 bp deletion
UB

GFP

IRES

PuroR

Corrected GFP sequence

*

1.75

With ZFNs
Without ZFNs

1.50
1.25
1.00
0.75
0.50
0.25
ND

0.00
ITR

CMV

ZFN1

ITR

ITR

ZFN2

CMV

c

ITR

AAV1.9

AAV ZFN vectors

d
Xhol digest

GTTATCCCTAAGCTTCGCGCCGAGGTGAAGTTCGAGGGCGACACC

CAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGA
GGGCGACACC

1

2

1

AAV6

ND
MXcell

e

CAAGGACGACGGCAACTACAAGACCTAAGCTCTCGAGATTACCCT

No digest

ND

AAV2

2

% GFP positive cells

LTR

b
% GFP positive cells

a

of homology upstream and 1,619 nucleotides downstream of the
35 bp insertion in GFP∆35. The donor plasmid was packaged
into recombinant AAV vectors (AAV2, AAV6, and AAV1.9), and
a hESC line carrying the mutated GFP was infected with these
gene-targeting constructs to test their capacity to mediate gene
correction and thereby restore GFP fluorescence. The levels of
gene correction achieved using recombinant AAV2 and AAV6
were below the limits of detection of flow cytometry in this assay
(Figure 4b), whereas the variant AAV1.9 was capable of targeted gene correction resulting in fluorescent hESCs (0.12%).
Furthermore, consistent with previous reports,3 we also show that
at similar efficiencies of gene delivery, AAV vectors can mediate targeted gene correction at rates much higher than plasmid
constructs (Figure 4b). Moreover, as discussed earlier, AAV1.9 is

10

With ZFNs
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1
0.1
0.01

0

10

20

30

Days

f

g

Figure 4 AAV1.9-mediated correction of a nonfunctional GFP expressed in hESCs. (a) Schematic overview depicting the targeting strategy for
the GFP gene correction. The defective GFP gene—GFP∆35, mutated by the insertion of a 35 bp fragment containing a translational stop codon13—
was integrated into HSF-6 cells using a lentiviral vector. A targeting vector (t37GFP) containing a 5′ truncated GFP coding sequence was packaged
into a recombinant AAV vector lacking a promoter. Homologous recombination between donor vector and integrated defective GFP∆35 gene would
correct the 35 bp mutation and result in fluorescent hESCs. (b) Gene targeting frequencies assessed as the percentage of GFP positive cells measured via flow cytometry 72 hours postinfection. Error bars indicate standard deviation (n = 3), *P < 0.01. ND, not detectable by flow cytometry.
(c,d) Representative analyses of the targeted correction of GFP∆35 gene. Genomic DNA from the “corrected” and “uncorrected” HSF-6 cells was
amplified using PCR. The 35 bp mutation within the GFP∆35 gene contains an Xho I site, and therefore only the PCR products from the “uncorrected”
cells (sample 2) can be digested using Xho I, whereas the PCR products from the corrected cells (sample 1) show the restoration of the functional GFP
gene without the Xho I site. DNA sequencing analysis also shows AAV1.9-mediated correction of the 35 bp mutation in HSF-6 cells originally expressing the mutated GFP∆35 gene. (e) Time course of AAV-mediated GFP∆35 correction in HSF-6 cells. Error bars indicate standard deviation (n = 3).
(f) Maintenance of an undifferentiated state of gene-corrected, GFP-expressing cells for 30 days postinfection. GFP positive HSF-6 cells, isolated via
FACS, were cultured for 30 days, then fixed and probed for the presence of GFP (green), Oct4 (red), and DAPI (blue). (g) Pluripotency of the HSF-6
cells carrying the corrected GFP gene was further confirmed through embryoid body-mediated in vitro differentiation to generate derivatives of all
three germ layers, as indicated by the expression of the ectodermal marker β-III tubulin, the mesodermal marker α-smooth muscle actin (α-SMA),
and the endodermal marker hepatocyte nuclear factor 3 β (HNF3β) after 24 days of differentiation (Bar = 100 μm). AAV, adeno-associated virus; CMV,
cytomegalovirus; DAPI, 4′,6-diamidino-2-phenylindole; FACS, fluorescent-activated cell sorting; GFP, green fluorescent protein; hESC, human embryonic stem cell; IRES, internal ribosome entry site; ITR, inverted terminal repeat; LTR, long terminal repeat.
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Table 2 Summary of gene targeting experiments and rates in various
human pluripotent lines in the presence and absence of ZFN-mediated
DSBs
Human
pluripotent
cell line

% Gene targeting
without ZFNs

% Gene targeting
with ZFNs

AAV2

AAV1.9

AAV2

AAV1.9

ND

0.08 ± 0.02*

0.09 ± 0.04

1.2 ± 0.28*

0.02 ± 0.01

0.12 ± 0.03*

0.31 ± 0.07

1.6 ± 0.19*

MSC-iPSCs

ND

0.06 ± 0.01*

0.12 ± 0.04

1.3 ± 0.14*

hFib2-iPSCs

ND

0.06 ± 0.02*

0.16 ± 0.03

1.2 ± 0.19*

HSF-6 hESCs
H1 hESCs

Values reported as mean ± SD (n = 3).
AAV, adeno-associated virus; hESC, human embryonic stem cell; iPSC, induced
pluripotent stem cell; MSC, mesenchymal stem cell; ND, not detectable; ZFN,
zinc finger nuclease.
*P < 0.01.

also capable of higher gene delivery efficiency to H1 hESCs, and
MSC- and dermal fibroblast-derived hiPSCs (Figure 2e), and we
observe a corresponding increase in gene-targeting efficiencies
(0.06–0.12%) for these cell lines as well (Table 2).

Introduction of DSBs via ZFNs improves the
gene-targeting efficiencies of AAV vectors
Directed evolution thus created a novel AAV variant that mediates high levels of gene targeting in hESCs and hiPSCs, and previous reports indicate that in addition to enhancing the ability of
the donor DNA to mediate HR, complementary approaches such
as inducing local DSBs at the target locus can further enhance
gene targeting.37 Recent years have witnessed the development
of engineered restriction enzymes generated by fusing a DNA
cleavage domain either to a zinc finger or a TAL effector DNAbinding domain as a general approach to generate site-specific
double-stranded chromosomal breaks and thereby greatly stimulate homology-directed gene repair in a number of human cell
lines.10–13,16 These findings provided rationale to explore whether
stimulation of gene targeting by nuclease-mediated DSBs can be
combined with an evolved AAV to further enhance gene targeting in hPSCs. We first generated AAV vectors that expressed the
ZFNs from a CMV promoter to target a site 12 bp upstream of the
35 bp insertion in the GFP gene (Figure 4a).38 hPSCs harboring
the mutant GFP were infected with the two AAV vectors encoding
a GFP-specific ZFN, as well as the AAV donor vector (t37GFP),
and the gene-targeting efficiency was measured via flow cytometry to detect cells expressing the corrected GFP. In the presence
of a local DSB-mediated by ZFNs, we observe a fivefold to 13-fold
increase in AAV1.9-mediated gene-targeting rates (Figure 4b and
Table 2), from an already relatively high efficiency of 0.06–0.12%
to 1.2–1.6% across multiple hPSC lines. Also, while not as high
as with AAV1.9, using other AAV serotypes to deliver the donor
construct and ZFNs did yield measurable gene correction in all
cases, indicating the generality of using AAV to deliver both
donor and nuclease for enhanced HR (Figure 4b and Table 2).
Finally, we observed similar increases in gene-targeting efficiencies when we infected human pluripotent embryonic carcinoma
cells (NT2) and human embryonic kidney (HEK293T) cells harboring the mutant GFP with AAV2 vectors encoding the GFPspecific ZFN and the donor t37GFP plasmids, indicating the
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general utility of combining an AAV donor with DSBs at the target
locus (Supplementary Figure S2).
To verify correction of the GFP∆35 sequence, genomic DNA
from “corrected” (GFP positive cells isolated using fluorescenceactivated cell sorting) and “uncorrected” HSF-6 hESCs was subjected to PCR to amplify the GFP sequence. The 35 bp insert of
the mutated GFP cell line harbors a unique Xho I site that enabled
the confirmation of GFP correction by restriction digest analysis
(Figure 4c). Also, direct sequencing of the PCR fragments confirmed the correction of the mutated GFP∆35 gene (Figure 4d).
Furthermore, the GFP positive hESCs, purified via fluorescenceactivated cell sorting, were expanded and monitored by flow cytometry for 30 days, and >95% of cells maintained GFP expression
(Figure 4e). These cells also maintained a pluripotent state during
long-term culture following targeted gene correction as indicated
by the expression of the pluripotency marker Oct4 (Figure 4f) and
their ability to differentiate into cells originating from the three
germ layers via embryoid body formation in vitro (Figure 4g).
Finally, in addition to measuring targeted gene correction via
HR, we also assessed the frequency of random chromosomal integration of AAV1.9 vectors. HSF-6 hESCs harboring GFP∆35 were
infected with AAV1.9 donor constructs and cultured for 14 days.
The genomic DNA from the infected cells was subjected to PCR
to specifically amplify a 822 bp fragment that partially spanned
the AAV viral genome following the puromycin resistance gene
(Supplementary Figure S3a), a region that should not participate
in homologous recombination (Figure 4a) and would thus represent residual AAV sequence. This assay was calibrated by conducting PCR in parallel on naive hESC DNA samples spiked with
different amounts of AAV1.9 donor plasmid, ranging from 1 copy
of AAV plasmid per 400 cellular genome copies to 1 copy of AAV
plasmid per 20 cellular genome copies. Based on the quantification of the samples and the standards, ~1 copy of AAV1.9 genome
was present per 100 cells that were originally exposed to the vector (Supplementary Materials and Methods and Supplementary
Figure S3b), consistent with earlier reports that demonstrate low
risk of random genomic integration of AAV in human cells.37,39 To
determine whether introduction of site-specific DSBs using ZFNs
increases this low frequency of random integration, we coinfected
hESCs carrying the mutant GFP with AAV1.9 vectors encoding
the donor plasmid, as well as the GFP-specific ZFNs. We did not
observe a significant increase in the levels of random integration
in the presence of ZFNs (Supplementary Figure S3), which suggests that at least in this system the introduction of site-specific
DSBs may not have a strong effect on nonhomologous integration
frequencies of AAV vectors.37,39

Discussion
AAV has attracted increasing attention for its ability to safely and
efficiently mediate gene targeting in a variety of cell types.3,30,32
However, prior studies have indicated that naturally occurring
AAV serotypes are typically inefficient in transducing numerous classes of stem cells, which can limit also the application of
AAV-mediated gene targeting to hPSCs. Recently, two studies
have reported the natural serotype AAV3 as the most efficient
serotype for human pluripotent lines.31,40 In the hESC and hiPSC
cell lines we examined, we did not observe a higher efficiency for
www.moleculartherapy.org vol. 20 no. 2 feb. 2012
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AAV3 relative to other serotypes (Figure 2c and data not shown).
Moreover, the reported transduction efficiency for AAV3 in the
earlier studies was lower than 25% at a MOI of 200,000, and likely
as a result, the maximum reported gene-targeting frequency was
1.3 × 10−5.31 Collectively, these results indicate that different natural
serotypes may be suited for different hPSC lines, but importantly
that gene-targeting efforts in general may benefit from increasing
AAV’s delivery efficiency to hPSCs.
Directed evolution has proven to be a powerful approach to
create AAV vectors with novel capabilities, and we successfully
demonstrate that under appropriate selective pressures AAV can
evolve for improved transduction efficiencies in human pluripotent
stem cells. Specifically, we isolated a new AAV variant, AAV1.9,
that exhibited an enhanced infection efficiency of ~48% at a MOI
of 100,000. AAV1.9 harbors a single R459G mutation that lies in
close proximity to both the heparin and FGF receptor binding
domains of AAV2. This variant displayed a slightly higher affinity
for heparin compared to AAV2 (Figure 3a), though we observed
similar levels of AAV1.9 and AAV2 binding to hESCs (Figure 3c).
In their investigation of AAV2’s heparin-binding domain, Opie
et al. found that a R459A AAV2 mutant was incapable of infecting
HeLa cells, despite heparin-binding levels essentially the same as
AAV2.41 The authors hypothesized that the R459A mutation may
result in a defect in a later stage of viral infection.41 This finding,
in conjunction with our observations that similar percentages of
AAV2 and AAV1.9 bind to hESCs, suggests that the R459G mutation may increase hESC gene delivery by modulating viral infection at a point following initial cell-surface docking, for example
AAV structural rearrangement during heparan sulfate binding,42
subsequent binding to secondary receptors, or cellular entry.
Further studies are needed to elucidate such mechanisms.
An AAV variant with enhanced gene delivery to hESCs can
serve as a valuable tool for numerous applications. For example,
AAV could mediate the controlled overexpression of regulatory proteins, short hairpin RNAs, or microRNAs, which would enable basic
investigations of the roles of key factors in stem cell self-renewal or
lineage commitment, as well as therapeutic applications that rely
on the efficient generation of specific cell lineages. AAV has the
potential to remain episomal and thereby mediate transient expression of such factors, compared to typically constitutive expression
from lentiviral vectors, which may in some cases be advantageous.
Furthermore, increased gene delivery efficiencies afford the opportunity to deliver multiple cargos effectively. For example, a twofold
increase in the delivery of one AAV vector would translate to an
eightfold increase in the number of cells that would be transduced
with three vectors carrying three different transgenes (such as the
gene-targeting construct and two ZFN-encoding vectors utilized in
this study). Another consequence of generating AAV variants with
higher transduction efficiencies in stem cells is the corresponding
increase in gene-targeting efficiencies. When AAV1.9 was used
to mediate gene correction in HSF-6 hESCs, we observed genetargeting frequencies of 8 × 10−4, approximately tenfold higher than
the reported targeting frequencies mediated by naturally occurring
AAV serotypes.31,32 We have also observed that AAV1.9 allows for
increased gene delivery and gene-targeting efficiencies to the H1
hESC line, as well as dermal fibroblast- and MSC-derived iPSCs,
thus establishing the generality of the method.
Molecular Therapy vol. 20 no. 2 feb. 2012
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It was previously shown that AAV gene targeting could be
enhanced with a double-stranded DNA break introduced at the
target locus by the nuclease I-SceI,37,39 and our results build upon
this important prior work to show for the first time that AAV can
function effectively in conjunction with ZFNs, which can now be
engineered for genomic site specificity.10,12,13 In addition to ZFNs,
TALE truncation variants have recently been linked to the catalytic
domain of Fok I to yield a new class of nucleases that can generate
discrete edits or small deletions within endogenous human genes
and induce gene modification in human cells by both nonhomologous end joining and HR.16 Alternatively, the DNA recognition
properties of homing endonucleases can be re-engineered to yield
enzymes that recognize endogenous genes in human cells.43 Such
custom nucleases can be beneficial, as prior studies indicate that
gene-targeting frequencies vary from locus to locus and are lower
at nonexpressed genes,12,44 and the targeting efficiencies in this
study may have benefitted from the use of a lentiviral vector—
which preferentially integrates into active transcription units45—as
the target locus. Furthermore, researchers have observed that gene
correction, gene knock-in, and knock-out vectors exhibit varying
targeting frequencies.46,47 However, depending on the application,
it is important to note that an appropriate AAV has the potential
to mediate gene targeting at a given locus at rates that are sufficiently high to obviate the time, labor, and resources entailed in
generating a custom nuclease. Furthermore, as ZFNs and other
nucleases have the potential to exhibit off-target cleavage,48,49 the
use of effective donor DNA in the absence of DSBs offers certain
advantages.
In conclusion, we have used directed evolution to create a
novel AAV variant with a single-point mutation that exhibited
enhanced gene delivery efficiency, and subsequently gene targeting, in hPSCs. In addition, this work demonstrates that AAVmediated gene-targeting frequencies can be further enhanced in
the presence of targeted DSBs generated by the AAV vector codelivery of ZFNs. These findings suggest that AAV vectors may
find strong utility in investigations of stem cell biology and therapy, ranging from the generation of reporter cell lines to therapeutic gene correction.

Materials and Methods
Cell lines. Cell lines were cultured at 37 °C and 5% CO2 and, unless oth-

erwise mentioned, were obtained from the American Type Culture
Collection (Manassas, VA). HEK293T and NT2 cells were cultured
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum (Gibco, Carlsbad, CA) and 1% penicillin/streptomycin
(Invitrogen, Carlsbad, CA). CHO K1 and CHO pgsA cells were cultured
in F-12K medium (ATCC) supplemented with 10% fetal bovine serum
(Gibco) and 1% penicillin/streptomycin (Invitrogen). HSF-6 hESCs (UC
San Francisco) were cultured on Matrigel-coated cell culture plates (BD,
Franklin Lakes, NJ) in X-Vivo medium (Lonza, Norwalk, CT) supplemented with 80 ng/ml FGF-2 (PeproTech, Rocky Hill, NJ) and 0.5 ng/ml
TGF-β1 (R&D Systems, Minneapolis, MN). H1 hESCs (WiCell, Madison,
WI) and dermal fibroblast- and MSC-derived iPS cells (a kind gift from
George Q. Daley, Children’s Hospital Boston, Boston, MA) were cultured on Matrigel-coated cell culture plates (BD) in mTeSR1 maintenance
medium (Stem Cell Technologies, Seattle, WA).

Library generation and viral production. Four replication-competent viral

libraries were used as starting materials for selections on HSF-6 hESCs.
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A random mutagenesis library was generated by subjecting cap genes
from AAV2 and AAV6 to error-prone PCR using 5′-CATGGGAAA
GGTGCCAGACG-3′ and 5′-ACCATCGGCAGCCATACCTG-3′ as
forward and reverse primers, respectively, as previously described (EP
Library).23 Libraries consisting of AAV2 containing random 7-mer peptide inserts33 and AAV2 containing randomized cap loop regions25 were
also utilized. Finally, a library containing shuffled DNA from the wildtype AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, AAV9 cap genes was
packaged.24 Libraries were pooled for the selection steps. Following evolution, to create recombinant versions of selected viruses, the cap genes were
inserted into the pXX2 recombinant AAV packaging plasmid using Not I
and Hind III.23 Both the replication-competent AAV library and recombinant AAV vectors expressing GFP under the control of a CMV promoter were packaged using HEK293T cells using the calcium phosphate
transfection method, and the viruses were purified by iodixonal gradient
centrifugation and Amicon filtration.23,27 DNase-resistant genomic titres
were determined via quantitative PCR.23
Library selection and evolution. One selection step is defined as hESC infection using a starting library, rescue by addition of adenovirus serotype 5 (at
levels sufficient to induce a cytopathic effect 48 hours post-adenovirus infection), and harvest of successful variants. For each selection step, cells were
grown on Matrigel-coated plates to eliminate the use of feeder cells, which
could become infected and bias the selection towards viral variants that transduce the feeder layer. In addition, stromal cells were removed from the culture
using collagenase digestion before the viral harvest to prevent the selection of
viral variants that infect stromal cells instead of hESCs. One round of evolution consists of genetic diversification of the cap gene followed by three selection steps. Two rounds of evolution were performed, with clonal analysis
(cap gene sequencing and hESC gene delivery assay for each selected virus)
performed between each round of evolution. Following the third selection
step, AAV cap genes were isolated from the pool of successful AAV variants
and amplified via PCR. Cap genes were then sequenced at the University of
California, Berkeley DNA sequencing facility and analyzed using Geneious
software (Biomatters, Auckland, New Zealand). Three-dimensional models
of the AAV2 capsid (Protein Databank accession number 1LP3) were rendered in Pymol (DeLano Scientific, San Carlos, CA).
HPSC transduction analysis. The human pluripotent cell lines were

plated at a density of 105 cells/well 24 hours before infection. Cells were
infected with rAAV-GFP at an MOI of 104. Stromal cells were removed
from the hESC and the iPSC culture using collagenase digestion before
flow cytometry. The percentage of GFP positive cells was assessed 48 hours
postinfection using a Beckman-Coulter Cytomics FC 500 flow cytometer
(Beckman-Coulter, Brea, CA).
Immunofluorescence staining. Immunostaining was performed to visualize the expression of pluripotency markers following AAV infection and
gene targeting. HSF-6 hESCs were plated on a 24-well plate and infected
as described for the transduction analysis. Forty-eight hours postinfection,
cells were fixed in 4% paraformaldehyde for 15 minutes, washed three times
with phosphate-buffered saline (PBS), and blocked with 1% bovine serum
albumin (BSA) and 0.1% Triton X-100 in PBS for 30 minutes. Cells were
incubated overnight at 4 °C with a mouse anti-Oct-3/4 primary antibody
(1:200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA) or anti-Nanog
primary antibody (1:200 dilution, Santa Cruz Biotechnology). Cells were
then washed three times with PBS and incubated with a secondary fluorescent-conjugated Alexa Fluor 647 goat anti-mouse antibody (1:250 dilution, Invitrogen) for 2 hours, followed by 4′,6-diamidino-2-phenylindole
(DAPI) for nuclear staining (Invitrogen) for 15 minutes. Cells were imaged
using a Zeiss Axio Observer.A1 inverted microscope.
In vitro differentiation assay of pluripotency. Colonies of HSF-6 hESCs
were isolated from stromal cells by collagenase enzymatic treatment and
partially dissociated by gentle pipetting. The cells were cultivated as small
clusters (5–10 cells) in suspension culture in ultra low-attachment plates
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(Corning, Corning, NY) to generate embryoid bodies (EBs) in X-Vivo
medium. After 6 days, the EBs were transferred to plates precoated with
Matrigel and further differentiated for 24 days. Immunocytochemistry as
described above was used to investigate whether the cells express markers of the three germ layers using the following primary antibodies: ectodermal: rabbit anti-β-III tubulin (1:500 dilution; Covance, Princeton, NJ);
mesodermal: mouse anti-α-smooth muscle actin (1:500 dilution; Sigma, St
Louis, MO); endodermal: rabbit anti-hepatocyte nuclear factor 3 β (1:500
dilution; Millipore, Billerica, MA). Fluorescence images were acquired
using a Nikon TE2000E2 epifluorescence microscope.
In vitro transduction and cell binding analysis. To determine the hepa-

ran sulfate dependence of AAV2 and the selected mutant, CHO K1 and
CHO pgsA cells were plated at a density of 2.5 × 104 cells per well 24
hours before infection. Cells were infected with AAV2-GFP, AAV6-GFP,
or AAV1.9-GFP at MOIs ranging from 100–2,500.26 The percentage of
GFP positive cells was assessed 48 hours postinfection using a BeckmanCoulter Cytomics FC 500 flow cytometer.
To analyze cell-surface binding of AAV variants, cells were plated as
described for the hESC transduction analysis. Stromal cells were removed
from the hESC culture via collagenase digestion, and cells were incubated
at 4 °C for 10 minutes; 105 cells were incubated with rAAV-GFP (MOI
of 104) at 4 °C for 1 hour. Cells were washed twice with ice-cold PBS to
remove unbound virus. DNase-resistant genomic titers were determined
via quantitative PCR.
Heparin column chromatography. rAAV-GFP vectors were subjected to

heparin column chromatography as previously described.23 Briefly, 1010
vector genome containing AAV particles were loaded into a 1 ml HiTrap
heparin column (GE Healthcare, Piscataway, NJ) previously equilibrated
with 0.15 mol/l NaCl and 50 mmol/l Tris at pH = 7.5. Washes were performed using 1 ml volumes of Tris buffer containing increasing increments
of 50 mmol/l NaCl, starting at 150 mmol/l NaCl and ending at 750 mmol/l
NaCl, followed by a 1 mol/l NaCl wash. Genomic titres from each fraction
were determined via quantitative PCR.

Generation of mutant GFP hPSC lines. An internal ribosome entry site and

puromycin resistance gene cassette (IRES-PuroR) were cloned into the Eco
RI and Xho I sites of pFUGW (a kind gift from David Baltimore, California
Institute of Technology, Pasadena, CA) to replace the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and yield pFUGIP. Next, a mutant GFP sequence harboring a 35 bp insertion (GFP∆35)
(a kind gift from Matthew H. Porteus, University of Texas Southwestern
Medical Center, Dallas, TX) digested with Bam HI/Eco RI was inserted
in place of the GFP sequence of similarly digested pFUGIP to construct
pFUG∆35IP. The lentiviral vector carrying the mutated GFP was packaged
by the calcium phosphate transient transfection method.50 Briefly, 10 µg of
pFUG∆35IP, 5  μg of pMDL g/p PRE, 3.5 μg of pcDNA 3 IVS VSV-G, and
1.5 μg of pRSV Rev were transfected into HEK 293T cell lines (>70% confluency), which were cultured on 10 cm tissue culture plates under Iscove’s
modified Dulbecco’s medium (IMDM) supplemented by 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. The lentiviral vector was harvested and concentrated by ultracentrifugation (L8-55M Ultracentrifuge;
Beckman Coulter), followed by resuspension in 100 µl of PBS with 20%
sucrose. Stable hPSC lines expressing the mutant GFP was generated by
infection with the lentiviral vector, followed by puromycin selection (1 µg/
ml) for 1 week. GFP fluorescence was not detected in the GFP∆35 hPSCs,
as confirmed by flow cytometry.

Gene targeting assay. The donor plasmid was generated by subcloning
a truncated GFP gene missing the first 37 base pairs (t37GFP), internal ribosome entry site, and puromycin resistance gene cassette into
an AAV vector plasmid (pAAV CMV GFP SN), such that the resulting targeting vector lacked a promoter. The ZFN expression constructs,
driven by a CMV promoter, were generated by subcloning gene cassettes
www.moleculartherapy.org vol. 20 no. 2 feb. 2012
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containing the engineered zinc fingers targeting GFP (also a gift from
Matthew H. Porteus) into pAAV CMV GFP SN (detailed cloning steps
for the donor and ZFN expressing constructs available upon request). The
donor construct and the ZFN expressing constructs were then packaged
into the AAV2, AAV6, and AAV1.9 capsids. All viral vectors were harvested and purified as described earlier.
For gene-targeting experiments mediated by AAV, hPSCs were seeded
onto 12-well tissue culture plates at a density of 105 cells/well 24 hours
before AAV infection. The cells were infected with the AAV targeting
vectors at an MOI of 105. For targeting experiments in the presence
of ZFNs, the ZFN expressing vectors were added at an MOI of 105 to
the cells in addition to the AAV targeting vectors. For gene-targeting
experiments mediated by naked plasmid constructs, Rho kinase inhibitor
(ROCK inhibitor, Y-27632; CalBioChem, San Diego, CA) was added to
hPSC media 24 hours before electroporation. Cells were harvested using
collagenase digestion, resuspended at 106 cells/ml in 100 μl Bio-Rad
buffer (GPEB 2) containing 1 μg each of the donor plasmid and ZFN
expression plasmids, and electroporated using the Bio-Rad Gene Pulser
MXcell System (250 V, 500 μF, 1000 ohms; Bio-Rad, Hercules, CA). The
cells were replated on Matrigel-coated plates in hPSC culture medium
supplemented with ROCK inhibitor. The medium was replaced after 1 day.
The percentage of GFP positive cells was assessed 48 hours postinfection
using flow cytometry as described earlier.
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